Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Company Updates - Madrigal Pharmaceuticals experienced a significant drop in shares despite reporting fourth-quarter sales of $321 million for its liver disease drug Rezdiffra, exceeding consensus estimates by $10 million, with all metrics being positive [2] - Daiichi Sankyo appointed former Novartis executive John Tsai as the new global head of research and development, effective April 1, replacing Ken Takeshita [3] - Johnson & Johnson announced an investment of over $1 billion in a new cell therapy manufacturing facility in Pennsylvania, part of a broader $55 billion commitment to U.S. production by early 2029 [4] - Johnson & Johnson has temporarily paused enrollment in a mid-stage trial for an Alzheimer's vaccine co-developed with AC Immune, with the halt not related to new safety findings [5] - Novartis is collaborating with biotech startup Unnatural Products to develop a macrocyclic peptide drug, providing $100 million upfront and potentially $1.7 billion if the drug progresses [6] Industry Insights - The pharmaceutical industry is seeing significant investments in manufacturing and research, with companies like Johnson & Johnson committing substantial funds to U.S. production and new drug development initiatives [4][6] - The trend of appointing experienced executives from major pharmaceutical companies to lead research and development efforts indicates a focus on enhancing innovation and drug development capabilities within the industry [3]

Management said patient growth continued through the fourth quarter. The company reported ending the quarter with more than 36,250 patients on Rezdiffra, up from more than 29,500 at the end of the third quarter. Sibold noted the patient figure reflects the net of new starts and discontinuations.Sibold attributed the commercial performance to building the market “from scratch,” including prescriber education, establishing care pathways, expanding prescriber breadth and depth, and contracting for access. He a ...

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Insights - The annual transaction value of China's innovative drug licensing has surpassed $100 billion, marking a nearly tenfold increase over four years, with a total of $137.7 billion in licensing deals signed in 2025 [2] - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, have signed significant agreements with Chinese firms, indicating a strong interest in China's next-generation innovative drug development pipelines [3] - The average transaction size for licensing deals involving Chinese biopharmaceutical companies has significantly increased this year, with an average deal size of $1.3 billion, a 76% increase from 2025 and six times the average size in 2021 [4] Group 1 - In 2025, there were 186 licensing transactions involving Chinese companies, reflecting a growing trend in the biopharmaceutical sector [2] - The average upfront payment for licensing deals this year is $77.7 million, double that of 2025 and three times the average in 2021 [4] - Notable recent agreements include a strategic partnership between Innovent Biologics and Eli Lilly worth $8.85 billion, and a potential $18.5 billion collaboration between AstraZeneca and CSPC Pharmaceutical Group [4] Group 2 - Macquarie Capital predicts that oncology drugs will continue to attract global pharmaceutical companies, highlighting China's strong capabilities in chemical drug development [5] - Multinational companies are increasingly viewing China as a critical part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [5] - Vision Lifesciences reports that China leads the world in specific molecular types, with Chinese companies accounting for nearly 90% of global licensing transactions for antibody-drug conjugates (ADCs) [5]

根据数据提供商Pharmcube的最新数据，2025年，中国企业签署了1377亿美元总规模的对外许可 交易，较2021年增长了近10倍，交易数量达到186项。 2026.02. 14 本文字数：1085，阅读时长大约2分钟 作者 | 第一财经 钱童心 中国生物制药公司参与的新药对外许可授权交易在2025年再次创下历史新高，并突破了千亿美元大 关。 麦格理资本亚洲医疗保健研究部门预测，今年被视为肿瘤治疗基石的一类药物将继续吸引全球制药商 的关注。麦格理资本分析师指出，尽管中国在生物学领域的实力相较于美国仍有差距，但在化学领域 实力雄厚，跨国公司可以从中国企业获得有前景的分子授权，其成本低于大型企业内部研发成本。 麦格理资本在最近的一份报告中表示："许多跨国公司正将中国视为其全球研发基础设施的重要组成 部分。尤其是在一些公司面临专利悬崖之际，为了削减成本，这一点显得尤为重要。" 行业咨询公司Vision Lifesciences在去年12月发布的2026年生物技术许可展望报告中也指出，中国 在特殊分子类型方面处于世界领先地位。以热门的肿瘤疗法抗体偶联药物（ADC）为例，中国企业 占据了全球此类药物对外许可交易的近 ...

中国生物制药公司参与的新药对外许可授权交易在2025年再次创下历史新高，并突破了千亿美元大关。 上个月，阿斯利康宣布与中国石药集团达成一项潜在价值高达185亿美元的合作协议。通过该项交易， 阿斯利康获得石药集团的长效肽技术平台，有望开发出每月仅需给药一次的下一代GLP-1类减重疗法。 Pharmcube的数据显示，随着跨国企业对中国新药资产投资兴趣的加速增长，今年至今，中国药企对外 授权平均交易规模已达13亿美元，比2025年的水平增长76%，约为2021年平均水平的六倍。就预付款金 额来看，今年的平均预付款为7770万美元，较2025年的3880万美元翻了一番，约为2021年的三倍。 麦格理资本亚洲医疗保健研究部门预测，今年被视为肿瘤治疗基石的一类药物将继续吸引全球制药商的 关注。麦格理资本分析师指出，尽管中国在生物学领域的实力相较于美国仍有差距，但在化学领域实力 雄厚，跨国公司可以从中国企业获得有前景的分子授权，其成本低于大型企业内部研发成本。 麦格理资本在最近的一份报告中表示："许多跨国公司正将中国视为其全球研发基础设施的重要组成部 分。尤其是在一些公司面临专利悬崖之际，为了削减成本，这一点显得尤为重要 ...

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting licensing deals will surge to a fresh record this year. The value of such deals signed by ‌companies in the greater China region - which includes Hong Kong, Macau and Taiwan - rose nearly tenfold last year from 2021 to an unprecedented $137.7 billion, according ‌to data ...

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]

【瑞博生物】电话会小结 – 与Madrigal达成BD，6千万美元首付款+43亿美元里程碑【东吴医药朱国广团队】 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画，瑞博具备临床前到临床的转化经验和数据，因此可以倒算出临床前的数据要求，完全符合 要求，因此达成了合作。 ②MDRL已经是MASH领域先行者，MDRL拥有Rezdi ④对瑞博来说，MASH临床前数据优秀，但是并不是公司临床聚焦的方向，临床也很难做，最优解就是合作授 权。 ⑤达成合作的6个管线，并不相同，具有互补机制。 #未来2年内至少达到一个mash的IND，或有数kw美元的收入。 与BI的合作：BI与MDGl的靶点、适应症领域均有区别，BI更注重晚期肝病和并发症，聚焦FIC的科学突破性创新 靶点。 目前进展符合预期，已经拿到2个里程碑，预计与MDGL的合作管线同期会进入IND。 创新技术：肾靶向领先全球 + 其他的肝外递送早期资产 + 双靶点。 与MDGL的互补合作：MASH适应症大市场，双方互赢，①肝病非常适合小核酸去做，MDGL对未来临床需要达到 的效果有很好的刻画， ...